ChemicalBook > CAS DataBase List > Monoacylglycerol Lipase Inhibitor 21

Monoacylglycerol Lipase Inhibitor 21

Product Name
Monoacylglycerol Lipase Inhibitor 21
CAS No.
1643657-35-5
Chemical Name
Monoacylglycerol Lipase Inhibitor 21
Synonyms
MAGL Inhibitor 21;WAFJKVGCIWVHQC-UHFFFAOYSA-N;Monoacylglycerol Lipase Inhibitor 21;1,3-Benzodioxol-5-ylmethyl 6-(4-biphenylyl)hexanoate;[1,1'-Biphenyl]-4-hexanoic acid, 1,3-benzodioxol-5-ylmethyl ester
CBNumber
CB03152694
Molecular Formula
C26H26O4
Formula Weight
402.48
MOL File
1643657-35-5.mol
More
Less

Monoacylglycerol Lipase Inhibitor 21 Property

Boiling point:
549.0±39.0 °C(Predicted)
Density 
1.165±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
≤21mg/ml in ethanol;0.5mg/ml in DMSO;30mg/ml in dimethyl formamide
form 
crystalline solid
color 
off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
16964
Product name
Monoacylglycerol Lipase Inhibitor 21
Purity
≥98%
Packaging
5mg
Price
$61
Updated
2024/03/01
Cayman Chemical
Product number
16964
Product name
Monoacylglycerol Lipase Inhibitor 21
Purity
≥98%
Packaging
10mg
Price
$112
Updated
2024/03/01
Cayman Chemical
Product number
16964
Product name
Monoacylglycerol Lipase Inhibitor 21
Purity
≥98%
Packaging
50mg
Price
$468
Updated
2024/03/01
Cayman Chemical
Product number
16964
Product name
Monoacylglycerol Lipase Inhibitor 21
Purity
≥98%
Packaging
100mg
Price
$816
Updated
2024/03/01
TRC
Product number
M524620
Product name
MonoacylglycerolLipaseInhibitor21
Packaging
5mg
Price
$55
Updated
2021/12/16
More
Less

Monoacylglycerol Lipase Inhibitor 21 Chemical Properties,Usage,Production

Uses

Monoacylglycerol Lipase Inhibitor 21 is an enzyme governing the inactivation of endocannabinoid 2-arachidonoglycerol (2-AG)MAGL inhibitors display analgesic and tissue-protecting effects.

Uses

Endocannabinoids such as 2-arachidonoyl glycerol (2-AG; ) and arachidonoyl ethanolamide (AEA; ) are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid (CB) receptors. Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) mediate the hydrolysis of AEA and 2-AG, respectively. Monoacylglycerol Lipase Inhibitor 21 selectively binds to MAGL (Ki = 0.4 μM) and reversibly blocks the enzyme’s activity in mouse brain with an IC50 value of 0.18 μM. Comparatively, Monoacylglycerol Lipase Inhibitor 21 is reported to inhibit FAAH activity in mouse brain with an IC50 value of 59 μM. This compound does not bind CB1 or CB2 receptors and does not inhibit the related serine hydrolases ABHD6 and ABHD12 (Kis > 10 μM). In a mouse model of multiple sclerosis, 5 mg/kg of Monoacylglycerol Lipase Inhibitor 21 has been used to ameliorate progression of the disease without producing detrimental CB1-mediated effects.[Cayman Chemical]

Biological Activity

ki: 0.4 μm for maglmonoacylglycerol lipase inhibitor 21 is an inhibitor of monoacylglycerol lipase (magl) and faah.endocannabinoids such as 2-arachidonoyl glycerol (2-ag) and arachidonoyl ethanolamide (aea) are biologically active lipids involved in various synaptic processes including activation of cannabinoid receptors. fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl) mediate the hydrolysis of aea and 2-ag, respectively.

in vitro

a previous study confirmed that monoacylglycerol lipase inhibitor 21 could inhibit magl in a reversible manner. moreover, the kinetic studies indicated that monoacylglycerol lipase inhibitor 21 acted as a noncompetitive inhibitor. in addition, monoacylglycerol lipase inhibitor 21 did not bind cb1 or cb2 receptors. furthermore, the selectivity of monoacylglycerol lipase inhibitor 21 was studied in a broad panel that includes a variety of receptors and enzymes, and the results showed that monoacylglycerol lipase inhibitor 21 did not inhibit significantly any of the analyzed targets [1].

in vivo

multiple sclerosis (ms) mouse model was used to evaluated the in-vivo efficacy of monoacylglycerol lipase inhibitor 21. treatment started at day 6 post-immunization and consisted of daily injections of monoacylglycerol lipase inhibitor 21 (5 mg/kg, i.p.) for the following 21 days. results showed that the administration of monoacylglycerol lipase inhibitor 21 could clearly ameliorate the progression of the disease, as assessed by the significantly lower clinical score in the ms model. this improvement correlated with an increase of the 2-ag levels in the spinal cord of treated animalsand with evident changes at the histological level, as monoacylglycerol lipase inhibitor 21 was able to significantly decrease leukocyte infiltration and microglial response, prevent axonal damage, as well as partially restore myelin morphology in eae mice [1].

References

[1] hernández-torres, g. ,cipriano, m.,hedén, e., et al. a reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. angewandte chemistry international edition english 53(50), 13765-13770 (2014).

Monoacylglycerol Lipase Inhibitor 21 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Monoacylglycerol Lipase Inhibitor 21 Suppliers

ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80

1643657-35-5, Monoacylglycerol Lipase Inhibitor 21Related Search:


  • Monoacylglycerol Lipase Inhibitor 21
  • WAFJKVGCIWVHQC-UHFFFAOYSA-N
  • 1,3-Benzodioxol-5-ylmethyl 6-(4-biphenylyl)hexanoate
  • MAGL Inhibitor 21
  • [1,1'-Biphenyl]-4-hexanoic acid, 1,3-benzodioxol-5-ylmethyl ester
  • 1643657-35-5